New Jersey needs turnkey lab space, faster approvals to compete for life sciences users

Experts say New Jersey faces a growing challenge: While it’s still a major draw for pharmaceutical research and development, speed to market has become increasingly important to life sciences users. That means the state’s lack of move-in-ready lab space — and its lengthy approval process for new construction — puts it at a disadvantage to competing markets.

Thor kicks off construction to create new lab, R&D building in Jersey City, JLL says

Thor Equities has started construction in its plan to overhaul a 350,000-square-foot building in Jersey City, where it aims to create “lab-ready” space that will attract life sciences users.

NKF inks sale of 181,000 sq. ft. R&D facility to Thor Equities

An investment firm has expanded its New Jersey life sciences portfolio with the acquisition of a research facility in Somerset County, in a transaction arranged by Newmark Knight Frank.

Life sciences breeding positive momentum in the New Jersey CRE market

The nation’s life sciences sector continues to expand, boosted by technological advancements, growing employment and a strong economy. While Boston and San Francisco remain the country’s main life sciences hub, their tightening inventory and constrained labor force has driven momentum south to the Garden State.

Repositioned life sciences campus in Bridgewater under new ownership, new platform

A joint venture is reaping the rewards of a plan to reposition a sprawling research and development complex in Bridgewater, having sold the campus for more than $150 million. All the while, the deal has cast a light on the allure of life sciences as a real estate investment class and the power of collaboration by brokers across multiple geographic markets.

NKF touts $152 million sale of Bridgewater life sciences campus

A joint venture has reaped more than $150 million from the sale of a high-profile life sciences campus in Bridgewater, under a recent transaction by Newmark Knight Frank.